BioRestorative Therapies
BRTX
13 hedge funds and large institutions have $383K invested in BioRestorative Therapies in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
1.07% less ownership
Funds ownership: 4.76% → 3.69% (-1.1%)
7% less funds holding
Funds holding: 14 → 13 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
30% less capital invested
Capital invested by funds: $545K → $383K (-$162K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$62.1K |
| 2 |
State Street
Boston,
Massachusetts
|
+$16K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$15.7K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.44K |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
+$19 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$103K |
| 2 |
SG
StoneX Group
New York
|
-$54.3K |
| 3 |
VF
Virtu Financial
New York
|
-$35K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.35K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$1.45K |
BRTX Hedge Fund Activity: Q4 2025 in Review
13 of the 8,256 institutional investors tracked by Wall St. Rank reported a position in BioRestorative Therapies (BRTX) for Q4 2025, worth a combined $383K — down 30% from $545K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BRTX and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 4 added.
The largest buyer was DRW Securities, opening a new position worth an estimated $62.1K. The largest seller was Citadel Advisors, cutting an estimated $103K.
- 13 institutional investors held BioRestorative Therapies (BRTX) as of Q4 2025, down from 14 in Q3 2025.
- Funds reported $383K of BioRestorative Therapies stock for Q4 2025, down 30% quarter-over-quarter.
- 3 funds opened new BioRestorative Therapies positions in Q4 2025 and 4 closed out, a net change of -1 holder.
- The largest BioRestorative Therapies buyer in Q4 2025 was DRW Securities, an estimated $62.1K added.
- The largest BioRestorative Therapies seller in Q4 2025 was Citadel Advisors, an estimated $103K sold.
Based on aggregated 13F filings for Q4 2025.